![\"\"](\"https:\/\/www.newsbeep.com\/nz\/wp-content\/uploads\/2026\/05\/Hims-Hers-1024x576.png\")
Hims & Hers. Photo: BusinessWire<\/p>\nHims & Hers Health, Inc., one of the leading health and wellness platforms, announced on May 21st the availability of generic semaglutide through its platform for eligible customers in Canada. This makes affordable GLP-1 treatment accessible to Canadians for whom cost has long been a barrier to treatment. For eligible customers, personalised treatment plans are available starting at USD 149\/month CAD.<\/p>\n
GLP-1 treatments have transformed obesity and metabolic health, with their significance extending well beyond weight alone.\u00a0Nearly two-thirds of Canadian adults\u00a0are overweight or living with obesity, but cost has remained a significant barrier to accessing the treatment they need. Health Canada\u2019s authorisation of generic semaglutide marks a turning point, not just for Hims & Hers customers, but for the country\u2019s broader healthcare landscape. This will help create a more dynamic GLP-1 market. As more providers offer access to affordable options, prices fall across the board, expanding access for patients regardless of where they seek care.<\/p>\n
Through Hims & Hers, eligible customers in Canada will have access to personalised care plans that may include GLP-1 options, alongside unlimited and ongoing Care Team access and evidence-informed resources built around nutrition, movement, and sleep, all designed to support sustainable, lasting health habits. All Canadian customers are connected with Canadian providers who understand the healthcare landscape they\u2019re navigating and bring the local expertise and clinical rigour this kind of care demands.<\/p>\n
\u201cGenerics have always played a critical role in expanding access to medicines that change lives,\u201d said Dr Sandy Van, Obesity Medicine Specialist and Chief Medical Officer, Hims & Hers Canada. \u201cToday marks a turning point: more choice, lower costs, and a genuine commitment to care built around the whole patient. Every Canadian deserves access to the treatment that\u2019s right for them, regardless of what they can afford.\u201d<\/p>\n
Hims & Hers. Photo: BusinessWire<\/p>\n
\u201cCanada has a strong health system, and we are committed to helping support and strengthen it,\u201d said Austin Kouri, General Manager, Hims & Hers Canada. \u201cBringing generic semaglutide to market means more Canadians have a real, affordable path to treatment. When patients have options and costs come down, everyone benefits. That\u2019s exactly the kind of impact we\u2019re here to create.\u201d<\/p>\n
Hims & Hers is committed to putting the right tools, the right providers, and the right support into the hands of Canadians who are ready to take control of their health.<\/p>\n
Generic semaglutide is authorised for sale by Health Canada for the management of Type 2 diabetes. It may be prescribed off-label for weight management in a licensed healthcare provider\u2019s sole clinical judgment. Hims & Hers Canada Inc. does not currently offer access to treatment services for Type 2 diabetes.<\/p>\n
Source<\/a><\/p>\n More related news:<\/p>\n Westinghouse AP300 Small Modular Reactor Approved for UK\u2019s Generic Design Assessment<\/a><\/p>\n WHOOP Enhances Health Platform with Clinician Access and AI Tools<\/a><\/p>\n